Experimental drug stimulates the immune system against myeloma

A study, published recently in Nature Medicine, has demonstrated that the experimental drug LCL-161 causes robust anti-myeloma activity through stimulation of the immune system. LCL-161 is a small-molecule inhibitor of apoptosis (IAP) which was originally developed to promote tumour cell death via apoptosis. However, in this study robust anti-myeloma activity was observed via upregulation of…

Details